Domain presents the best-in-class potential of its EP4 antagonist drug candidate at the AACR 2020
Check out our virtual posters ! Available on our website and at the #AACR20 from June 22, 2020 at 9:00 AM EDT.
DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best in class properties (Poster #6697), presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrates its best-in-class potential.
Share this article